Nepal Launches Favipiravir Treatment Study

Nepal Health Research Council has decided to test antiviral medicine favipiravir (Avigan) on COVID-19 patients admitted to hospitals in Kathmandu and Pokhara, reported Arjun Poudel, with local media. The influenza medicine, which is being administered under a phase-III trial, will be given to 600 patients with mild or moderate symptoms of the disease caused by SARS-CoV-2 virus infections.

Favipiravir is being manufactured by Deurali-Janta Pharmaceuticals Pvt. Ltd, located in Nepal.